

# Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity	ABN/ARSN
Sigma Pharmaceuticals Limited	15 088 417 403

We (the entity) give ASX the following information.

### Information about buy-back

1	Type of buy-back	On-market buy-back
2	Date Appendix 3C was given to ASX	13 September 2012

### Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

	Before previous day	Previous day	
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	62,591,102	172,000
4	Total consideration paid or payable for the shares/units	\$44,908,822	\$98,264

**Appendix 3E**  
**Daily share buy-back notice**

---

Before previous day	Previous day
---------------------	--------------

5	If buy-back is an on-market buy-back	<table border="1"> <tr> <td style="vertical-align: top;">Highest price paid: \$0.8525</td> <td style="vertical-align: top;">Highest price paid: \$0.5750</td> </tr> <tr> <td style="vertical-align: top;">Lowest price paid: \$0.5600</td> <td style="vertical-align: top;">                     Lowest price paid: \$0.5700                       Highest price allowed under rule 7.33: \$0.6017                 </td> </tr> </table>	Highest price paid: \$0.8525	Highest price paid: \$0.5750	Lowest price paid: \$0.5600	Lowest price paid: \$0.5700  Highest price allowed under rule 7.33: \$0.6017
Highest price paid: \$0.8525	Highest price paid: \$0.5750					
Lowest price paid: \$0.5600	Lowest price paid: \$0.5700  Highest price allowed under rule 7.33: \$0.6017					

**How many shares/units may still be bought back?**

6	If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back	55,867,250
---	---	------------

**Compliance statement**

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

*or, for trusts only:*

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust’s constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here:  
 (Director/Company secretary)

Date: 4 November 2013

Print name: SUE MORGAN

== == == == ==

---